Allspring Global Investments Holdings LLC Acquires 32,850 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Allspring Global Investments Holdings LLC raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 466.9% in the fourth quarter, HoldingsChannel reports. The firm owned 39,886 shares of the company’s stock after buying an additional 32,850 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Amphastar Pharmaceuticals were worth $2,467,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the company. Exchange Traded Concepts LLC grew its stake in shares of Amphastar Pharmaceuticals by 0.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after purchasing an additional 169 shares during the period. Guidance Capital Inc. grew its stake in shares of Amphastar Pharmaceuticals by 3.9% during the 3rd quarter. Guidance Capital Inc. now owns 7,152 shares of the company’s stock valued at $321,000 after purchasing an additional 267 shares during the period. Los Angeles Capital Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 1.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock valued at $1,262,000 after purchasing an additional 358 shares during the period. Bank of Montreal Can grew its stake in shares of Amphastar Pharmaceuticals by 2.9% during the 1st quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock valued at $477,000 after purchasing an additional 371 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 4.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 9,457 shares of the company’s stock valued at $543,000 after purchasing an additional 380 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price target for the company. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $66.00.

Amphastar Pharmaceuticals Stock Up 3.5 %

AMPH stock opened at $40.01 on Monday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $35.62 and a twelve month high of $67.66. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock has a market cap of $1.96 billion, a P/E ratio of 15.51, a PEG ratio of 0.95 and a beta of 0.84. The business’s 50-day moving average price is $45.96 and its 200-day moving average price is $51.14.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.43 EPS for the current year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,000 shares of company stock valued at $660,860. Corporate insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.